OxTalks will soon move to the new Halo platform and will become 'Oxford Events.' There will be a need for an OxTalks freeze. This was previously planned for Friday 14th November – a new date will be shared as soon as it is available (full details will be available on the Staff Gateway).
In the meantime, the OxTalks site will remain active and events will continue to be published.
If staff have any questions about the Oxford Events launch, please contact halo@digital.ox.ac.uk
Limiting the severity of inflammation and its eventual resolution are critical pathways which are vital to minimizing damage to host tissues. We study the ability of the biologics otelixizumab (anti-CD3) and adalimumab (anti-TNF) to induce a potent CD8+FOXP3+ regulatory T cell (Treg) population in rheumatoid arthritis patients. These Treg can suppress CD4+ T cell proliferation and IL-17 and IFN-γ production; however their mechanism of action is unknown. We have been studying how monocytes are crucial for the induction of FOXP3 expression in CD8+ T cells and how CD8+ T cells can control their ability to become a Treg via p38 phosphorylation.
Our studies aim to 1) identify novel therapeutic targets that may mimic Treg function or 2) enhance the efficacy of biologic drugs used in the clinic to treat RA and type 1 diabetes by the use of combination therapy.
